BTT 2027 / Acorda - LARVOL DELTA

Association of AOC3 expression in visceral adipose tissue and circulating soluble VAP-1 with arterial stiffness assessed by cardio-ankle vascular index in Japanese patients with severe obesity. (PubMed, Obes Facts) - "Visceral fat-derived AOC3 expression correlates with serum sVAP-1 concentration that appears to contribute to arterial stiffness in obesity. In contrast, subcutaneous fat may be associated with reduced SSAO activity. These findings highlight the fat depot-specific role of adipose tissue in vascular health and implicate VAP-1 as a potential mediator of obesity-related atherosclerosis."

Journal • Atherosclerosis • Cardiovascular • Gastrointestinal Disorder • Genetic Disorders • Obesity • AOC3

Therapeutic Potential of Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibitors: Current Medicinal Chemistry and Emerging Opportunities. (PubMed, Med Res Rev) - "Here in we have highlighted important aspects of the compounds investigated in therapeutic applications. Furthermore, we have outlined potential avenues for innovation with the aim of maximizing the therapeutic efficacy of VAP-1/SSAO inhibitors in clinical settings."

Journal • Review • Inflammation • Oncology • AOC3

"Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity #obesity #vascular @inserm @UT3PaulSabatier @sanofi @universitelaval @UniTurku https://t.co/sqVOnMA55w" (@JPBY_official)

Preclinical • Genetic Disorders • Obesity • AOC3

Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases. (PubMed, Front Pharmacol) - "Recent findings revealed that VAP-1 is expressed in atherosclerotic plaques and treatment with VAP-1 inhibitors alleviates the progression of atherosclerosis. This review will focus on the roles of VAP-1/SSAO in the progression of atherosclerotic lesions and therapeutic potentials of VAP-1 inhibitors for cardiovascular diseases."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Inflammation • Myocardial Infarction • AOC3

"Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity @inserm @UT3PaulSabatier @sanofi @universitelaval @UniTurku #obesity #vascular https://t.co/sqVOnMA55w" (@JPBY_official)

Preclinical • Genetic Disorders • Obesity • AOC3

Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity. (PubMed, J Physiol Biochem) - "These results suggest that the lack of oxidase activity found in AOC3KI is sufficient to reproduce the metabolic disturbances observed in AOC3KO mice, save those related with cholesterol transport. Modulation of SSAO activity therefore constitutes a potential target for the treatment of cardiometabolic diseases, especially obesity when complicated by low-grade inflammation."

Journal • Preclinical • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • AOC3 • IL6

Inhibition of Semicarbazide-sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-fed New Zealand White Rabbits. (PubMed, Sci Rep) - "Treatment with PXS-4728A, a selective VAP-1/SSAO inhibitor, in cholesterol-fed rabbits significantly decreased SSAO-specific hydrogen peroxide generation in the aorta and reduced atherosclerotic plaques. VAP-1/SSAO inhibition also lowered blood low-density lipoprotein cholesterol, reduced the expression of adhesion molecules and inflammatory cytokines, suppressed recruitment and activation of macrophages, and decreased migration and proliferation of SMC. In conclusion, VAP-1/SSAO inhibition reduces atherosclerosis and may act through suppression of several important mechanisms for atherosclerosis."

Journal